NET CONNECT has summarised highlights from the recent ENETS 2019 meeting for you. Bio-markers in NENs by Dr Kira Oleinikov, Hadassah-Hebrew University Medical Center, Israel

Dr Kira Oleinikov, MD Senior physician, Neuroendocrine Tumor Unit and ENETS Center of Excellence, Endocrinology Department, Division of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. Following an initial training in molecular biology, Dr Kira Oleinikov successfully completed an internal medicine and endocrinology specialization in 2017. In August 2018, Kira joined the Neuroendocrine Tumor Unit & ENETS Center of Excellence team at Hadassah-Hebrew University Medical Center in Jerusalem, one of the major clinical and research units in NETs internationally, as a full-consultant position. Kira is actively involved in all programs running at the Hadassah NET unit, including clinical programs (seeing NET patients in the clinic/departments or as part of the regular patient follow-up/recruitment inside clinical trials); NET laboratory research; teaching programs (both medical and post-graduate students at the Hadassah Faculty of Medicine); NET patient's advocacy group activities, and more. Kira is a member of the European Neuroendocrine Tumor Society (ENETS) and the Israeli Endocrine Society. Kira's sharp intellectual abilities driven her to a variety of academic achievements during her fellowship in molecular biology at the Hebrew University. She is continuously involved in the diagnostic and the therapeutic decision-making process of NET patients with a variety of tumors, and established herself already as a highly prepared clinician in the field. Nowadays, Kira's main research interest is focused on the evaluation of different treatment approaches to pancreatic NETs, as well as in developing new biomarkers for lung carcinoids. Additionally, she spends a significant part of her time in the unit basic research laboratory, aiming to examine the possible anti-tumorigenic effect of different drug combinations in a NET liver metastasis mice model, in an attempt to overcome drug-resistance. At a personal level, the combination of knowledge, tenacity, and good communications skills found in Kira is truly unique, making her an excellent partner for the COR2E program in NETs.

Programme summary
Watch the video now
Other episodes of this series
NET CONNECT Update from ENETS 2019

NET CONNECT Update from ENETS 2019

Episode 2 Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from Ipsen
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Ipsen
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
NET CONNECT

NET CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Ipsen, Eisai Europe Limited, ITM and Boehringer Ingelheim

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Highlights from ESMO 2026

Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers

Experts
Dr Elizabeth Smyth, Dr Yelena Janjigian, Assoc. Prof. Gerald Prager, Prof. Hong Jae Chon, Assoc. Prof. Lorenza Rimassa, Dr Tom Newsom-Davis, Dr Louise Lim, Dr Komal Jhaveri, Dr Roberto Iacovelli
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
MET crusaders
  • clock 3 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education

podcast Video podcast
Oncology 
Metastatic TNBC cannot wait

Optimising 1st line TROP2 ADC decisions in metastatic triple-negative breast cancer

Experts
Prof. Giuseppe Curigliano, Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca.